Do I need a prescription for Isoniazid 400mg/5ml oral solution?

Isoniazid 400mg/5ml oral solution is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Isoniazid 400mg/5ml oral solution?

Isoniazid 400mg/5ml oral solution is the generic name. It is available under brand names including: Isoniazid 400mg/5ml oral solution. (Source: NHS dm+d — Actual Medicinal Products)

Isoniazid 400mg/5ml oral solution

Prescription only

Requires a prescription from a doctor or prescriber

Oral solution

400mg/5ml

Oral

Antibacterial agent used primarily as a tuberculostatic.

Active ingredients:

Isoniazid

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 05.01.09

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC J04AC01

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Isoniazid

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Isoniazid

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Isoniazid

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Isoniazid

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

1 branded products available

1 productsShow details

1 products

Possibly available on the UK marketRestricted supplyDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Isoniazid on the MHRA register

Isoniazid 400mg/5ml oral solution

Special Order

None

Special

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Daily doseShow details

WHO defined daily dose (DDD)

300 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similarShow details

Isoniazid 300mg/5ml solution for injection ampoules

Injection

300mg/5ml

Same therapeutic group

Isoniazid 100mg/5ml solution for injection ampoules

Injection

100mg/5ml

Same therapeutic group

Isoniazid 300mg tablets

Tablet

300mg

Same therapeutic group

Isoniazid 30.5mg/5ml oral solution

Oral solution

30.5mg/5ml

Same therapeutic group

Isoniazid 300mg/5ml oral solution

Oral solution

300mg/5ml

Same therapeutic group

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Isoniazid

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

NICE clinical guidance(1)

Tuberculosis (NG33)

NG33

NICE guideline

Updated Feb 2024

Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Isoniazid

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

12641811000001102

dm+d ID

12641811000001102

VTM (Virtual Therapeutic Moiety)

776412002

VMP (Virtual Medicinal Product)

12641811000001102

BNF code

05010900

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

J04AC01

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

186 found

Half-life

0.5 to 1.6 hours

Mechanism

Isoniazid is a prodrug and must be activated by bacterial catalase.

Food interactions

8 warnings

Human targets

None mapped

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

Readily absorbed following oral administration; however, may undergo significant first pass metabolism.…

Half-life

0.5 to 1.6 hours

Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.

Protein binding

0-10%

Very low (0-10%)

Metabolism

Primarily hepatic. Isoniazid is acetylated by N -acetyl transferase to N -acetylisoniazid; it is then biotransformed to isonicotinic acid and monoacetylhydrazine.…

Elimination

24 hours

From 50 to 70 percent of a dose of isoniazid is excreted in the urine within 24 hours.

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.

Properties:

solid

Avg. mass: 137.14 Da

DrugBank indication

Isoniazid is used for the treatment of all forms of tuberculosis in which organisms are susceptible. It is also used in combination with rifampin and pyrazinamide.
[L45369]

Also known as(101)

4-pyridinecarbohydrazide

INH

Isoniazid

Isoniazida

Isonicotinic acid hydrazide

Isonicotinic hydrazide

Isonicotinohydrazide

Isonicotinoylhydrazide

Dosage forms(46)

Tablet (Oral)

Tablet, coated (Oral) — 100 mg

Tablet, coated (Oral) — 300 mg

Tablet (Oral)

Capsule (Oral) — 50 mg/5mL

Injection, solution (Intramuscular) — 100 mg/1mL

Solution (Oral) — 50 mg/5mL

Syrup (Oral) — 50 mg/5mL

Molecular properties(19)

Drug interactions(1820)

Known interactions with other medications. Always consult a healthcare professional.

Cilostazol

Unknown severity

DB01166

The serum concentration of Cilostazol can be increased when it is combined with Isoniazid.

Check this interaction

Citalopram

Unknown severity

DB00215

The serum concentration of Citalopram can be increased when it is combined with Isoniazid.

Check this interaction

Brexpiprazole

Moderate

DB09128

The metabolism of Brexpiprazole can be decreased when combined with Isoniazid.

Check this interaction

Clopidogrel

Moderate

DB00758

The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Isoniazid resulting in a loss in efficacy.

Check this interaction

Eliglustat

Moderate

DB09039

The metabolism of Eliglustat can be decreased when combined with Isoniazid.

Check this interaction

Everolimus

Moderate

DB01590

The metabolism of Everolimus can be decreased when combined with Isoniazid.

Check this interaction

Flibanserin

Moderate

DB04908

The metabolism of Flibanserin can be decreased when combined with Isoniazid.

Check this interaction

Ibrutinib

Moderate

DB09053

The metabolism of Ibrutinib can be decreased when combined with Isoniazid.

Check this interaction

Ivabradine

Moderate

DB09083

The metabolism of Ivabradine can be decreased when combined with Isoniazid.

Check this interaction

Ivacaftor

Moderate

DB08820

The metabolism of Ivacaftor can be decreased when combined with Isoniazid.

Check this interaction

Lurasidone

Moderate

DB08815

The metabolism of Lurasidone can be decreased when combined with Isoniazid.

Check this interaction

Naloxegol

Moderate

DB09049

The metabolism of Naloxegol can be decreased when combined with Isoniazid.

Check this interaction

Olaparib

Moderate

DB09074

The metabolism of Olaparib can be decreased when combined with Isoniazid.

Check this interaction

Ranolazine

Moderate

DB00243

The metabolism of Ranolazine can be decreased when combined with Isoniazid.

Check this interaction

Sonidegib

Moderate

DB09143

The metabolism of Sonidegib can be decreased when combined with Isoniazid.

Check this interaction

Avanafil

Moderate

DB06237

The metabolism of Avanafil can be decreased when combined with Isoniazid.

Check this interaction

Eplerenone

Moderate

DB00700

The metabolism of Eplerenone can be decreased when combined with Isoniazid.

Check this interaction

Colchicine

Moderate

DB01394

The metabolism of Colchicine can be decreased when combined with Isoniazid.

Check this interaction

Fentanyl

Moderate

DB00813

The metabolism of Fentanyl can be decreased when combined with Isoniazid.

Check this interaction

Iloperidone

Moderate

DB04946

The metabolism of Iloperidone can be decreased when combined with Isoniazid.

Check this interaction

Retapamulin

Moderate

DB01256

The metabolism of Retapamulin can be decreased when combined with Isoniazid.

Check this interaction

Tofacitinib

Moderate

DB08895

The metabolism of Tofacitinib can be decreased when combined with Isoniazid.

Check this interaction

Vardenafil

Moderate

DB00862

The metabolism of Vardenafil can be decreased when combined with Isoniazid.

Check this interaction

Eszopiclone

Moderate

DB00402

The metabolism of Eszopiclone can be decreased when combined with Isoniazid.

Check this interaction

Zopiclone

Moderate

DB01198

The metabolism of Zopiclone can be decreased when combined with Isoniazid.

Check this interaction

Lovastatin

Moderate

DB00227

The metabolism of Lovastatin can be decreased when combined with Isoniazid.

Check this interaction

Phenytoin

Unknown severity

DB00252

The serum concentration of Phenytoin can be increased when it is combined with Isoniazid.

Check this interaction

Fosphenytoin

Unknown severity

DB01320

The serum concentration of Fosphenytoin can be increased when it is combined with Isoniazid.

Check this interaction

Cycloserine

Unknown severity

DB00260

The risk or severity of adverse effects can be increased when Isoniazid is combined with Cycloserine.

Check this interaction

Caffeine

Unknown severity

DB00201

The serum concentration of Caffeine can be increased when it is combined with Isoniazid.

Check this interaction

Theophylline

Unknown severity

DB00277

The serum concentration of Theophylline can be increased when it is combined with Isoniazid.

Check this interaction

Dyphylline

Unknown severity

DB00651

The serum concentration of Dyphylline can be increased when it is combined with Isoniazid.

Check this interaction

Pentoxifylline

Unknown severity

DB00806

The serum concentration of Pentoxifylline can be increased when it is combined with Isoniazid.

Check this interaction

Mercaptopurine

Unknown severity

DB01033

The serum concentration of Mercaptopurine can be increased when it is combined with Isoniazid.

Check this interaction

Aminophylline

Unknown severity

DB01223

The serum concentration of Aminophylline can be increased when it is combined with Isoniazid.

Check this interaction

Oxtriphylline

Unknown severity

DB01303

The serum concentration of Oxtriphylline can be increased when it is combined with Isoniazid.

Check this interaction

Theobromine

Unknown severity

DB01412

The serum concentration of Theobromine can be increased when it is combined with Isoniazid.

Check this interaction

Fenethylline

Unknown severity

DB01482

The serum concentration of Fenethylline can be increased when it is combined with Isoniazid.

Check this interaction

8-azaguanine

Unknown severity

DB01667

The serum concentration of 8-azaguanine can be increased when it is combined with Isoniazid.

Check this interaction

7,9-Dimethylguanine

Unknown severity

DB01978

The serum concentration of 7,9-Dimethylguanine can be increased when it is combined with Isoniazid.

Check this interaction

Xanthine

Unknown severity

DB02134

The serum concentration of Xanthine can be increased when it is combined with Isoniazid.

Check this interaction

7-Deazaguanine

Unknown severity

DB02245

The serum concentration of 7-Deazaguanine can be increased when it is combined with Isoniazid.

Check this interaction

Guanine

Unknown severity

DB02377

The serum concentration of Guanine can be increased when it is combined with Isoniazid.

Check this interaction

9-Methylguanine

Unknown severity

DB02489

The serum concentration of 9-Methylguanine can be increased when it is combined with Isoniazid.

Check this interaction

Peldesine

Unknown severity

DB02568

The serum concentration of Peldesine can be increased when it is combined with Isoniazid.

Check this interaction

Hypoxanthine

Unknown severity

DB04076

The serum concentration of Hypoxanthine can be increased when it is combined with Isoniazid.

Check this interaction

9-Deazaguanine

Unknown severity

DB04356

The serum concentration of 9-Deazaguanine can be increased when it is combined with Isoniazid.

Check this interaction

Propentofylline

Unknown severity

DB06479

The serum concentration of Propentofylline can be increased when it is combined with Isoniazid.

Check this interaction

Valomaciclovir

Unknown severity

DB06575

The serum concentration of Valomaciclovir can be increased when it is combined with Isoniazid.

Check this interaction

3-isobutyl-1-methyl-7H-xanthine

Unknown severity

DB07954

The serum concentration of 3-isobutyl-1-methyl-7H-xanthine can be increased when it is combined with Isoniazid.

Check this interaction

Showing 50 of 1820 interactions

Food & lifestyle interactions

Advice

Administer vitamin supplements. Vitamin B6 (pyridoxine) should be given with isoniazid to prevent deficiency.

Avoid Alcohol

Avoid alcohol. Avoid drinking alcoholic beverages such as unpasteurized beer; unless approved by your physician, as they may contain tyramine. Consuming alcohol may also increase the risk of isoniazid induced hepatitis and neuropathy.

Caffeine Notice

Avoid chocolate. Chocolate contains caffeine, which should be limited during isoniazid therapy.

Advice

Avoid histamine-containing foods and supplements. Histamine-containing foods (e.g., skipjack, tuna, other tropical fish) can cause headaches, sweating, palpitations, flushing, and hypotension.

Avoid Alcohol

Avoid tyramine-containing foods and supplements. Tyramine-containing foods include cheese, red wine, fava beans, pickled food, cured food, and alcoholic beverages.

Caffeine Notice

Limit caffeine intake.

Empty Stomach

Take on an empty stomach. Take at least 1 hour before or 2 hours after meals.

Advice

Take separate from antacids. Taking this medication with antacids can reduce absorption.

Toxicity & overdose

LD₅₀ 100 mg/kg (Human, oral). Adverse reactions include rash, abnormal liver function tests, hepatitis, peripheral neuropathy, mild central nervous system (CNS) effects. In vivo, Isoniazid reacts with pyridoxal to form a hydrazone, and thus inhibits generation of pyridoxal phosphate.

Isoniazid also combines with pyridoxal phosphate; high doses interfere with the coenzyme function of the latter.

How it works

Mechanism of action

Isoniazid is a prodrug and must be activated by bacterial catalase. Specficially, activation is associated with reduction of the mycobacterial ferric KatG catalase-peroxidase by hydrazine and reaction with oxygen to form an oxyferrous enzyme complex. Once activated, isoniazid inhibits the synthesis of mycoloic acids, an essential component of the bacterial cell wall. At therapeutic levels isoniazid is bacteriocidal against actively growing intracellular and extracellular Mycobacterium tuberculosis organisms. Specifically isoniazid inhibits InhA, the enoyl reductase from Mycobacterium tuberculosis, by forming a covalent adduct with the NAD cofactor. It is the INH-NAD adduct that acts as a slow, tight-binding competitive inhibitor of InhA.

Pharmacodynamics

Isoniazid is a bactericidal agent active against organisms of the genus Mycobacterium, specifically M. tuberculosis, M. bovis and M. kansasii. It is a highly specific agent, ineffective against other microorganisms. Isoniazid is bactericidal when mycobacteria grow rapidly and bacteriostatic when they grow slowly.

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Readily absorbed following oral administration; however, may undergo significant first pass metabolism. Absorption and bioavailability are reduced when isoniazid is administered with food.

Half-life

Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.

Protein binding

Very low (0-10%)

Metabolism

Primarily hepatic. Isoniazid is acetylated by N -acetyl transferase to N -acetylisoniazid; it is then biotransformed to isonicotinic acid and monoacetylhydrazine. Monoacetylhydrazine is associated with hepatotoxicity via formation of a reactive intermediate metabolite when N-hydroxylated by the cytochrome P450 mixed oxidase system.

The rate of acetylation is genetically determined. Slow acetylators are characterized by a relative lack of hepatic N -acetyltransferase.

Route of elimination

From 50 to 70 percent of a dose of isoniazid is excreted in the urine within 24 hours.

Metabolizing enzymes(9)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

NAT2Arylamine N-acetyltransferase 2

substrate

CYP2A6Cytochrome P450 2A6

inhibitor

CYP2C8Cytochrome P450 2C8

inhibitor

CYP2E1Cytochrome P450 2E1

substrate

inhibitor

inducer

CYP1A2Cytochrome P450 1A2

inhibitor

CYP2C9Cytochrome P450 2C9

inhibitor

CYP2D6Cytochrome P450 2D6

inhibitor

CYP2C19Cytochrome P450 2C19

inhibitor

CYP3A4Cytochrome P450 3A4

inhibitor

Carriers(1)

Proteins that carry this drug through the body

Albumin

BE0000530

ALB

Specific functionantioxidant activity

Cellular location

Secreted

General function & pharmacology

Binds water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs (Probable). Its main function is the regulation of the colloidal osmotic pressure of blood (Probable). Major zinc transporter in plasma, typically binds about 80% of all plasma zinc .
PMID:19021548
Major calcium and magnesium transporter in plasma, binds approximately 45% of circulating calcium and magnesium in plasma (By similarity).

Potentially has more than two calcium-binding sites and might additionally bind calcium in a non-specific manner (By similarity). The shared binding site between zinc and calcium at residue Asp-273 suggests a crosstalk between zinc and calcium transport in the blood (By similarity). The rank order of affinity is zinc > calcium > magnesium (By similarity).

Binds to the bacterial siderophore enterobactin and inhibits enterobactin-mediated iron uptake of E.coli from ferric transferrin, and may thereby limit the utilization of iron and growth of enteric bacteria such as E.coli .
PMID:6234017
Does not prevent iron uptake by the bacterial siderophore aerobactin PMID:6234017

ATC classification(12 codes)

ATC J04AM04

ATC J04AM01

ATC J04AM03

ATC J04AM02

ATC J04AM09

ATC J04AM06

ATC J04AC01

ATC J04AM05

ATC J04AM07

ATC J04AM08

ATC J04AM12

ATC J04AC51

Affected organisms(2)

Mycobacteria

Mycobacterium tuberculosis

International brands(7)

Experimental properties(5)

External resources(2)

RxList Drugs.com

Protein Data Bank entries(12)

Commercial products(123)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Isoniazid

DB00951

CAS number

54-85-3

UNII (FDA)

V83O1VOZ8L

InChI Key (molecular fingerprint)

QRXWMOHMRWLFEY-UHFFFAOYSA-N

Additional database identifiers

Drugs Product Database (DPD)

6618

ChEBI

6030

PubChem Compound

3767

PubChem Substance

46506039

KEGG Compound

C07054

KEGG Drug

D00346

ChemSpider

3635

BindingDB

50336507

PharmGKB

PA450112

PDB

NIZ

Therapeutic Targets Database

DAP000011

Wikipedia

Isoniazid

ChEMBL

CHEMBL64

ZINC

ZINC000000001590

RxCUI

6038

UniProtKB

P9WIE5

UniProt Accession

KATG_MYCTU

UniProtKB

P9WGR1

UniProt Accession

INHA_MYCTU

UniProtKB

P9WNX1

UniProt Accession

DYR_MYCTU

HUGO Gene Nomenclature Committee (HGNC)

HGNC:7646

GeneCards

NAT2

GenBank Gene Database

D90040

GenBank Protein Database

219412

UniProtKB

P11245

UniProt Accession

ARY2_HUMAN

UniProtKB

P9WJI5

UniProt Accession

NAT_MYCTU

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2610

GenAtlas

CYP2A6

GeneCards

CYP2A6

GenBank Gene Database

X13897

Guide to Pharmacology

1321

UniProtKB

P11509

UniProt Accession

CP2A6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2622

GenAtlas

CYP2C8

GeneCards

CYP2C8

GenBank Gene Database

M17397

Guide to Pharmacology

1325

UniProtKB

P10632

UniProt Accession

CP2C8_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2631

GeneCards

CYP2E1

GenBank Gene Database

J02625

GenBank Protein Database

181360

Guide to Pharmacology

1330

UniProtKB

P05181

UniProt Accession

CP2E1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2596

GenAtlas

CYP1A2

GeneCards

CYP1A2

GenBank Gene Database

Z00036

Guide to Pharmacology

1319

UniProtKB

P05177

UniProt Accession

CP1A2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2623

GenAtlas

CYP2C9

GeneCards

CYP2C9

GenBank Gene Database

AY341248

Guide to Pharmacology

1326

UniProtKB

P11712

UniProt Accession

CP2C9_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2625

GenAtlas

CYP2D6

GeneCards

CYP2D6

GenBank Gene Database

M20403

GenBank Protein Database

181350

Guide to Pharmacology

1329

UniProtKB

P10635

UniProt Accession

CP2D6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2621

GeneCards

CYP2C19

GenBank Gene Database

M61854

GenBank Protein Database

181344

Guide to Pharmacology

1328

UniProtKB

P33261

UniProt Accession

CP2CJ_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:399

GenAtlas

ALB

GeneCards

ALB

GenBank Gene Database

V00494

GenBank Protein Database

28590

UniProtKB

P02768

UniProt Accession

ALBU_HUMAN

International reference pricing

7 formulations

Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.

From $0.11/g

To $27.37/ml

Isoniazid powder

$0.11/g

Isoniazid 50 mg/5ml Syrup

$0.16/ml

Isoniazid 300 mg tablet

$0.18/tablet

Isoniazid 100 mg tablet

$0.28/tablet

Rifamate capsule

$4.19/capsule

Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 30 days ago(4 Mar 2026)

Back to medicines

Isoniazid 400mg/5ml oral solution

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

British National Formulary

NICE clinical guidance(1)

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Metabolism

Elimination

Clinical essentials

Pharmacology

Deep science
10

Chemical identifiers

Isoniazid

Additional database identifiers

International reference pricing

DrugBank citations

Isoniazid 400mg/5ml oral solution

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

NICE clinical guidance(1)

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Metabolism

Elimination

Clinical essentials

Pharmacology

Deep science10

Chemical identifiers

Isoniazid

Additional database identifiers

International reference pricing

DrugBank citations

Deep science
10